Nikoo Bayan

Dr. Nikoo Bayan

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MOMohammad Amin Dabbagh Ohadi
Mohammad Amin Dabbagh Ohadi
MAMir Sajjad Aleyasin
Mir Sajjad Aleyasin
RSReza Samiee
Reza Samiee
SBSanaz Bordbar
Sanaz Bordbar
SMS. Farzad Maroufi
S. Farzad Maroufi
TSTimothy R. Smith
Timothy R. Smith
Differentiating glioma from primary central nervous system lymphoma (PCNSL) can be challenging, and current diagnostic measures such as MRI and biopsy are of limited efficacy. Liquid biopsies, which detect circulating biomarkers such as microRNAs (miRs), may provide valuable insights into diagnostic biomarkers for improved discrimination. This review aimed to investigate the role of specific miRs in diagnosing and differentiating glioma from PCNSL. A systematic search was conducted of PubMed, Scopus, Web of Science, and Embase for articles on liquid biopsies as a diagnostic method for glioma and PCNSL. Sixteen dysregulated miRs were identified with significantly different levels in glioma and PCNSL, including miR-21, which was the most prominent miR with higher levels in PCNSL, followed by glioma, including glioblastoma (GBM), and control groups. The lowest levels of miR-16 and miR-205 were observed in glioma, followed by PCNSL and control groups, whereas miR-15b and miR-301 were higher in both tumor groups, with the highest levels observed in glioma patients. The levels of miR-711 were higher in glioma (including GBM) and downregulated in PCNSL compared to the control group. This review suggests that using these six circulating microRNAs as liquid biomarkers with unique changing patterns could aid in better discrimination between glioma, especially GBM, and PCNSL.


6 April 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
HGHamidreza Ghanbari
Hamidreza Ghanbari
NBNikoo Bayan
Nikoo Bayan
SRShakiba Rahimi
Shakiba Rahimi
FSFarhad Salari
Farhad Salari
MDMohammadreza Toghyani DolatAbadi
Mohammadreza Toghyani DolatAbadi
MSMohammad Soleimani
Mohammad Soleimani
Ocular surface tumors (OSTs) are rare but potentially life-threatening neoplasms encompassing entities such as ocular surface squamous neoplasia (OSSN), conjunctival melanoma, and lymphoma. Accurate diagnosis often requires expert ophthalmologists and pathologists, compounded by the reliance on advanced imaging modalities, with excisional biopsy being the gold standard. These limitations underscore the need for less invasive, accessible diagnostic approaches, where artificial intelligence (AI) holds significant promise. This review provides a comprehensive overview of AI advancements in OST management. It begins with definitions of AI and its key branches, followed by an examination of AI models applied to ophthalmic tumors using imaging data. Current developments in AI-related diagnostic tools for OSTs are discussed, highlighting their potential to enhance patient management, with classifications based on imaging modalities and specific OST types. Finally, the review addresses main challenges in AI implementation, including data limitations and ethical considerations, while outlining future directions to integrate AI into clinical ophthalmology practice. By bridging technological innovation with clinical needs, AI shows promise in OST diagnosis and management, ultimately improving outcomes in this challenging condition.

16 September 2024 in Journal of Ophthalmic and Vision Research
Verified
Journal Article
Open access
PDF file
HRHamid Riazi-Esfahani
Hamid Riazi-Esfahani
AAAmin Ahmadi
Amin Ahmadi
RSReza Sadeghi
Reza Sadeghi
MMMasoud Mirghorbani
Masoud Mirghorbani
FGFariba Ghassemi
Fariba Ghassemi
AMAhmad Mirshahi
Ahmad Mirshahi
Purpose: This study aimed to compare macular vascular changes one and three months after treatment with either panretinal photocoagulation (PRP) or intravitreal bevacizumab (IVB). Methods: A total of 62 eyes with very severe non-proliferative diabetic retinopathy or early proliferative diabetic retinopathy without center-involved diabetic macular edema, were included in this retrospective study. Thirty-nine eyes were allocated to the PRP group, while 23 eyes were treated with IVB. Optical coherence tomography angiography (OCTA) was performed to measure foveal avascular zone (FAZ) characteristics as well as the densities of superficial and deep capillary plexuses (SCP and DCP). Results: In the IVB group, the FAZ area and perimeter expanded at month one but returned to baseline level after three months. In the PRP group, however, the FAZ area and perimeter were rather steady. Changes in the FAZ area were significantly different between the treatment groups at month one (P = 0.02), but not at month three (P = 0.31). There was no significant difference in the change in FAZ circularity index between the two groups at each time point (P = 0.55 and P = 0.31). Similarly, changes in SCP density were not statistically significant between the two groups at both time points (all Ps > 0.05). A comparison of the two treatment arms based on the mean change in DCP density revealed a significant difference at month one, but not at month three (P = 0.01 and P = 0.49, respectively). Conclusion: Although bevacizumab and PRP have different short-term macular vascular responses, both therapies have the ability to normalize or stabilize vascular measures over time.